Inhibition of B-Catenin Signaling for Treatment of Hepatocellular Carcinoma

抑制 B-连环蛋白信号转导治疗肝细胞癌

• 批准号: 7990951
• 负责人: Julian A Simon
• 金额: $ 22.97万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7990951
• 关键词: Address; Adverse effects; Antineoplastic Agents; BAY 54-9085; Biological Assay; Cancer Etiology; Cancer cell line; Cause of Death; Cell Adhesion; Cell Line; Cell Proliferation; Cells; Cessation of life; Clinical Trials; Cytotoxic agent; Data; Development; Diagnosis; Disease; Dose; Drug Kinetics; Evaluation; Gene Mutation; Gene Targeting; Genes; Genetic; Genetic Determinism; Genetic Transcription; Goals; Growth; Hand; Hepatitis C; Human; In Vitro; Incidence; Lead; Light; Malignant Epithelial Cell; Malignant neoplasm of liver; Measures; Modality; Modeling; Molecular; Molecular Genetics; Mus; Mutation; New Agents; Nexavar; Nuclear; Operative Surgical Procedures; Outcome; Pathway interactions; Patients; Peroxisome Proliferator-Activated Receptors; Pharmaceutical Preparations; Placebos; Primary carcinoma of the liver cells; Proliferating; Property; Proteins; Public Health; Quality of life; Radiation; Research; Resistance; Route; Schedule; Signal Pathway; Signal Transduction; Solid Neoplasm; Specificity; Staging; Structure-Activity Relationship; Testing; Toxic effect; Toxicology; Transcriptional Activation; United States; Universities; World Health Organization; Xenograft Model; Xenograft procedure; analog; base; beta catenin; cell motility; chemotherapy; design; drug discovery; effective therapy; follow-up; global health; in vivo; in vivo Model; information gathering; inhibitor/antagonist; kinase inhibitor; member; mouse model; novel therapeutics; outcome forecast; peroxisome; pre-clinical; prevent; programs; public health relevance; receptor; research clinical testing; small molecule; tumor; tumor xenograft

DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is a major public health problem with few effective treatment options. In an effort to develop new treatment modalities, we have identified a class of small molecule agents that disrupt the beat-catenin pathway, one of the major signaling pathways in many, if not most, HCC tumors. The wnt (wingless and int-1)/b-catenin signaling pathway is critical for vertebrate development but is also aberrantly activated in a number of tumor types including HCC. Wnt/b-catenin signaling integrates cell-adhesion and motility signals with growth, proliferation and survival. In molecular terms, beta-catenin is a transcriptional regulator that interacts with a number of co-repressors and co-activators to regulate the transcription of target genes. In HCC mutations in b-catenin itself or in genes encoding proteins that regulate beta-catenin stability lead to elevated levels of nuclear b-catenin and transcriptional activation of cellular proliferation and survival programs. New agents that target specific aspects of beta-catenin signaling present the opportunity to target HCC tumors in a selective and efficacious manner. The goal of the research proposed in this application is to validate a new class of compounds directed against the wnt-b-catenin pathway using in vitro (cell-based) and in vivo (mouse xenograft) studies. In the first Specific Aim, 544 analogues of our current lead compound will be tested in our HepG2 cell-based assay. In Aim 2, a panel of human cancer cell lines will be examined for sensitivity to a five best b-catenin inhibitors. Sensitive cell lines and active compounds will be selected for evaluation using in vivo models of HCC. The inhibitors will be tested for in vivo toxicity as well as pharmacokinetic properties in mice in the third Specific Aim. Finally, in the fourth Specific Aim, sensitive cell lines will be used in mouse xenograft models using optimized dose and route of administration of active compounds to demonstrate in vivo efficacy. Together these studies will validate beta-catenin inhibitors as anti- HCC pre-clinical candidates. The long-term goal of this research is to move this class of compounds into human clinical trials. PUBLIC HEALTH RELEVANCE: Liver cancer is a major cause of death throughout the world. There are very few effective treatments for liver cancer and consequently, the prognosis for patients with this disease is poor. The research outlined here will evaluate a group of compounds that block a key pathway involved in liver cancer as potential anticancer drugs. If successful, these studies will provide a new therapeutic option for the treatment of liver cancer.

描述（由申请人提供）：肝细胞癌（HCC）是一个主要的公共卫生问题，有效的治疗方案很少。在努力开发新的治疗方式，我们已经确定了一类小分子药物，破坏节拍-连环蛋白途径，在许多，如果不是大多数，肝癌肿瘤的主要信号通路之一。wnt（wingless and int-1）/b-连环蛋白信号通路对脊椎动物发育至关重要，但在包括HCC在内的许多肿瘤类型中也被异常激活。Wnt/β-连环蛋白信号将细胞粘附和运动信号与生长、增殖和存活整合。在分子水平上，β-连环蛋白是一种转录调节因子，它与许多共阻遏物和共激活物相互作用以调节靶基因的转录。在HCC中，β-连环蛋白本身或编码调节β-连环蛋白稳定性的蛋白质的基因中的突变导致核β-连环蛋白水平升高以及细胞增殖和存活程序的转录激活。靶向β-连环蛋白信号传导的特定方面的新药物提供了以选择性和有效的方式靶向HCC肿瘤的机会。本申请中提出的研究目标是使用体外（基于细胞）和体内（小鼠异种移植）研究来验证一类针对wnt-b-连环蛋白通路的新化合物。在第一个特定目标中，我们目前的先导化合物的544种类似物将在我们的HepG 2细胞检测中进行测试。在目标2中，将检查一组人类癌细胞系对五种最佳β-连环蛋白抑制剂的敏感性。将选择敏感的细胞系和活性化合物用于使用HCC的体内模型进行评价。将在第三个特定目的中检测抑制剂的体内毒性以及小鼠中的药代动力学特性。最后，在第四个特定目的中，敏感细胞系将用于小鼠异种移植模型，使用活性化合物的优化剂量和给药途径，以证明体内疗效。这些研究将共同验证β-连环蛋白抑制剂作为抗HCC临床前候选药物。这项研究的长期目标是将这类化合物用于人体临床试验。 公共卫生相关性：肝癌是全世界的主要死亡原因。肝癌的有效治疗方法很少，因此，患有这种疾病的患者的预后很差。本文概述的研究将评估一组阻断肝癌相关关键途径的化合物作为潜在抗癌药物。如果成功，这些研究将为肝癌的治疗提供新的治疗选择。